- Aktuelle Seite:
-
Home
-
Harm Reduction / Schadensminderung
-
Naloxon
- Naloxon-Fachtag, 20.05.2017 in München, Veranstalter akzept e.V. und condrobs (München) - Bericht von Dr. Ingo Ilja Michels
Take Home Naloxone: best practice in preventing fatal opioid overdoses for prison leavers
(...) People leaving prison are at the highest risk of overdose and drug-related death in the first weeks following release. This is likely due to reduced tolerance to heroin, increased purity of drugs compared to those used in prison and the tendency of some released prisoners to return to previous drug use patterns.Increasing the uptake of Take Home Naloxone (THN) amongst opioid users leaving prison (and in the community) can help reduce the number of drug-related deaths amongst this high risk population. (The Forward Trust, UK, Pulse#7, Juni 2019)
https://www.forwardtrust.org.uk/media/1891/pulse-7-final.pdf
Pulmonary Complications of Opioid Overdose Treated With Naloxone.
Farkas A, Lynch MJ, Westover R, Giles J, Siripong N, Nalatwad A, Pizon AF, Martin-Gill C.
Ann Emerg Med. 2019 Jun 7. pii: S0196-0644(19)30309-9. doi: 10.1016/j.annemergmed.2019.04.006.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31182316
Naloxone interventions in opioid overdoses: a systematic review protocol.
Shaw LV, Moe J, Purssell R, Buxton JA, Godwin J, Doyle-Waters MM, Brasher PMA, Hau JP, Curran J, Hohl CM.
Syst Rev. 2019 Jun 11;8(1):138. doi: 10.1186/s13643-019-1048-y.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560883/
Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR.
JAMA Netw Open.Published online June 21, 20192(6):e196215. doi:10.1001/jamanetworkopen.2019.6215
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2736179
Naloxone urban legends and the opioid crisis: what is the role of public health?
Crabtree A, Masuda JR.
BMC Public Health. 2019 May 30;19(1):670. doi: 10.1186/s12889-019-7033-5.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543555/
Successful Naloxone Challenge Test in a Patient With Atrial Flutter.
Harlow TR, Peters JR, Anderson DL.
Prim Care Companion CNS Disord. 2019 May 23;21(3). pii: 18l02385. doi: 10.4088/PCC.18l02385.
https://www.psychiatrist.com/PCC/article/Pages/2019/v21n03/18l02385.aspx
Should we worry that take-home naloxone availability may increase opioid use?.
Tas, B., Humphreys, K., McDonald, R., and Strang, J. ( 2019)
Addiction, doi.org/10.1111/add.14637.
https://onlinelibrary.wiley.com/doi/10.1111/add.14637
USA. Naloxone Has Made Overdosing Less Terrifying
Some drug users say that as long as the lifesaving drug is around, they don’t worry as much about dying. (The Atlantic, USA, 08.06.2019)
Pharmacokinetic Interaction of Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.
Krieter PA, Chiang CN, Gyaw S, Skolnick P, Snyder R.
Drug Metab Dispos. 2019 Apr 16. pii: dmd.118.085977. doi: 10.1124/dmd.118.085977.
http://dmd.aspetjournals.org/content/dmd/early/2019/04/16/dmd.118.085977.full.pdf
Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal.
Heaton JD, Bhandari B, Faryar KA, Huecker MR.
J Emerg Med. 2019 Apr 5. pii: S0736-4679(19)30121-0. doi: 10.1016/j.jemermed.2019.02.015.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30961922
USA. Allowing Pharmacists to Directly Dispense Opioid Antidote Can Sharply Cut Opioid Overdose Deaths
Allowing pharmacists to dispense the opioid antidote naloxone without a physician's prescription can sharply reduce the incidence of fatal opioid-related overdoses, according to a new RAND Corporation study.
States that adopted such laws saw fatal opioid overdoses fall by an average of 27 percent during the second year following passage and 34 percent in subsequent years, according to the study published in the journal JAMA Internal Medicine. (RAND, USA, 06.05.2019)
https://www.rand.org/news/press/2019/05/06.html
Does Take-Home Naloxone Availability Increase Opioid Use?.
Tas, B., Humphreys, K., McDonald, R., and Strang, J. ( 2019)
Addiction, doi.org/10.1111/add.14637.
https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14637
USA. FDA approves first generic naloxone nasal spray to treat opioid overdose
Agency is also taking new steps to support development of over-the-counter and additional generics of naloxone to help reduce opioid overdose deaths, increase access to emergency treatment. (FDA – US Fodd and Drug Administration, 19.04.2019)
Evidence-Based Guidelines for EMS Administration of Naloxone.
Williams K, Lang ES, Panchal A, Gasper JJ, Taillac P, Gouda J, Hedges M.
Prehosp Emerg Care. 2019 Mar 29:1-41. doi: 10.1080/10903127.2019.1597955.
https://www.tandfonline.com/doi/full/10.1080/10903127.2019.1597955
Comparative Human Factors Evaluation of Two Nasal Naloxone Administration Devices: NARCAN® Nasal Spray and Naloxone Prefilled Syringe with Nasal Atomizer.
Tippey KG, Yovanoff M, McGrath LS, Sneeringer P.
Pain Ther. 2019 Mar 15. doi: 10.1007/s40122-019-0118-0.
https://link.springer.com/article/10.1007%2Fs40122-019-0118-0
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.
Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M.
Neuropsychopharmacology. 2019 Mar 13. doi: 10.1038/s41386-019-0368-x.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30867551
Evaluation and optimization of take-home naloxone in an academic medical center.
Cooler J, Ross CA, Robert S, Linder L, Ruhe AM, Philip A.
Ment Health Clin. 2019 Mar 1;9(2):105-109. doi: 10.9740/mhc.2019.03.105.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398357/
USA. Next-generation single-dose antidotes for opioid overdoses.
American Chemical Society. (ScienceDaily, USA, 31.03.2019)
https://www.sciencedaily.com/releases/2019/03/190331192537.htm
Opioid Overdose Reversal News: FDA-approved naloxone devices produce substantially higher blood levels of naloxone than improvised nasal spray
(...) A new study looked at how well the FDA-approved nasal spray and autoinjector compared to the improvised nasal devices, which are not FDA-approved. Scientists found that the approved naloxone devices deliver higher blood levels of naloxone than the improvised nasal devices. In fact, levels in the plasma concentration of naloxone are considerably lower when improvised devices are used. The FDA-approved 4-mg dose nasal spray produced the highest blood level of naloxone of all the products tested. (NIDA, USA, 15.03.2019)
Heroin body-packing and naloxone
Vahabzadeh, Maryam et al.
The Lancet , Volume 393 , Issue 10177 , e35
(Registrierung erforderlich)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30502-1/fulltext
The effects of heat and freeze-thaw cycling on naloxone stability
Dulcie Lai, Amy Trinh Pham, Praveen P. Nekkar Rao and Michael A. Beazely
Harm Reduction Journal 2019, 16:17, doi.org/10.1186/s12954-019-0288-4
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0288-4
Kratom (Mitragynine) Ingestion Requiring Naloxone Reversal.
Overbeek DL, Abraham J, Munzer BW.
Clin Pract Cases Emerg Med. 2019 Jan 4;3(1):24-26. doi: 10.5811/cpcem.2018.11.40588.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366391/
A novel naloxone training compared with current recommended training in an overdose simulation.
Franko TS 2nd, Distefano D, Lewis L.
J Am Pharm Assoc (2003). 2019 Feb 8. pii: S1544-3191(18)30590-9. doi: 10.1016/j.japh.2018.12.022.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30745190
Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder.
Phillips RH, Salzman M, Haroz R, Rafeq R, Mazzarelli AJ, Pelletier-Bui A.
Ann Emerg Med. 2019 Feb 14. pii: S0196-0644(19)30006-X. doi: 10.1016/j.annemergmed.2019.01.006.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30773411
Higher doses of naloxone are needed in the synthetic opiod era
Ronald B. Moss and Dennis J. Carlo
Substance Abuse Treatment, Prevention, and Policy, 2019, 14:6, doi.org/10.1186/s13011-019-0195-4
https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-019-0195-4
USA. FDA may recommend overdose reversal drug alongside opioid prescriptions
In a growing number of states, patients who get opioids for serious pain may leave their doctors' offices with a second prescription -- for naloxone, a drug that can save their lives if they overdose on the powerful painkillers. (CNN, USA, 20.02.2019)
https://edition.cnn.com/2019/02/20/health/opioids-naloxone-prescriptions-partner/index.html
Pharmacokinetics of a novel, approved, 1.4 mg intranasal naloxone formulation for reversal of opioid overdose - a randomised controlled trial.
Skulberg AK, Åsberg A, Khiabani HZ, Røstad H, Tylleskar I, Dale O.
Addiction. 2019 Jan 14. doi: 10.1111/add.14552.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30644628
Take-home naloxone: a life saver in opioid overdose
The Lancet , Volume 393 , Issue 10169 , 296
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30153-9/fulltext
Scotland's National Naloxone Programme
Bird, Sheila M et al.
The Lancet , Volume 393 , Issue 10169 , 316 - 318
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33065-4/fulltext
USA. FDA Takes Step to Allow Drug Companies to Sell Naloxone Without Prescription
USA. FDA Takes Step to Allow Drug ComThe U.S. Food and Drug Administration (FDA) has taken a step to make it easier for companies that make the opioid overdose antidote naloxone to sell the drug without a prescription, CNBC reports. Making naloxone available over-the-counter would lower costs and increase consumer access, the agency said. (drugfree.org, USA, 24.01.2019)
Seite 1 von 7